K-V Pharmaceutical Co. Opiniones

llegara a un entero en 30 dias que piensan

Con los cortos que le están metiendo yo la veo en 0,6, pero seguimos tb dependiendo del juez. Lo bueno es que sin noticias y en silencio es empujando hacia arriba!!

cada dia que pasa es una ventaja por que van en aumento ingrsos por makena

se nota, mueve poco volumen y empuja hacia arriba!!

Madre mia da miedo el volumen en cortos de la ultimas ordenes de esta ultima hora de mercado,vean esto aqui .http://uk.advfn.com/p.php?pid=trades&symbol=NO%5eKVPHQ

todo lo q esta en rojo es vol cortos , acaba de ejecutarse 150k en cortos.
Total cortos hasta 19.554 hrs 394k317 del total 515k343 negociados hasta esa hora, mas del 50%. .

Si sigue siendo shorteada como lo estan haciendo , lo veo difícil,el volumen aumenta pero a expensas de cortos. Será q quieren frenarle como las sesiones recientes o los Osos tienen informacion privilegiada.... ? Que opinais , pues el Stop Loss hay q ajustarlo pero con un Beta tan alto es complicado.

Ricard,Ontoro, LaKkcha q opinais de esto.

http://bankruptcynews.dowjones.com/article?an=DJFDBR0020130603e963j291c&r=wsjblog&ReturnUrl=http%3a%2f%2fbankruptcynews.dowjones.com%3a80%2farticle%3fan%3dDJFDBR0020130603e963j291c%26r%3dwsjblog

Silver Point Offers to Sponsor Plan for K-V Pharmaceutical
Stephanie Gleason
June 03, 2013
(c) 2013 Dow Jones & Company, Inc.
Senior bondholder Silver Point Finance LLC has submitted a proposal letter for K-V Pharmaceutical Co . that matches an offer from a group of investors holding subordinate bonds.
The subsidiary of hedge fund Silver Point Capital LP announced Friday that it is "prepared to sponsor a chapter 11 plan that is identical to the structure of the Convert Plan, but indisputably provides more value to the Debtors' estates and creditors," according to documents filed with the U.S. Bankruptcy Court in Manhattan.
Silver Point said that its first offer was a better deal for K-V, but the pharmaceutical company was on the verge of moving forward with the convertible bondholder investor group, so it is willing to match that deal.
The new Silver Point offer lowers to $5 million the breakup fee that would be required if the deal isn't ultimately executed. It reduces to 4.5% the amount of common stock Silver Point would be entitled to as a fee and increases to $10.25 million the recovery for unsecured creditors.
A previous offer from the convertible group---which is composed of funds controlled by Greywolf Capital, Capital Venture International, Deutsche Bank Securities Inc . and Kingdon Associates---required a $7.5 million breakup fee, a 5% common stock fee and provided $10 million to unsecured creditors.
Silver Point would also sponsor a rights offering for $210 million and would directly purchase $65 million worth of K-V's new stock. The $210 million rights offering would last for three days, during which time convertible bondholders could purchase those shares, otherwise they revert to Silver Point.
The letter from Silver Point doesn't specifically lay out how much stock the direct purchase or the rights offering entitles it to. However, Silver Point called its proposal "identical" to the one offered by the convertible group.
The rights offering under that proposal was for $200 million---10 million shares at $20 per share. The group's proposed $75 million direct stock purchase gave them 24% equity. Together, the group potentially could have ended up with 88% equity in the new K-V if all the shares in the offering reverted to the group.
Valuing the shares, Silver Point would wind up with 20.8% equity for its $65 million and is offering 67.2% equity in the rights offering. It would also end up with an 88% stake if it got all the rights offering shares.
Silver Point is part of a group of senior bondholders and bankruptcy lenders, which also includes Whitebox Advisors LLC and Pioneer Investment Management, owed $225 million plus interest in bonds and $85 million in bankruptcy financing. Those bondholders were being paid in cash in full under the convertible group-sponsored plan.
Convertible bondholders, owed $200 million, are entitled to participate in the rights offering and receive 7% common stock under both plans.
K-V filed for Chapter 11 protection in August, embroiled in controversy over its preterm labor drug, Makena. The only drug with Food and Drug Administration approval to prevent preterm labor, Makena was expected to rake in profits for the company.
However, when K-V rolled out its pricing structure, $1,500 per injection, the medical community pushed back and didn't prescribe it, instead continuing to give patients a compounded version that cost far less.
The FDA declined to act to stop the cheaper versions from being produced by compounding pharmacies, and sales of Makena stayed low. Since then, sales of the drug have increased as compounding practices have come under scrutiny.
Write to Stephanie Gleason at [email protected].

dificil saber pero makena vale mas